A
Accellix
Aims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results
About Accellix
Accellix, Inc. specializes in providing advanced flow cytometry solutions designed to enhance the speed, accuracy, and reproducibility of cell and gene therapy applications. The company operates in the life sciences and biotechnology markets, serving clients that range from research institutions to pharmaceutical companies. Accellix's core product is a fully automated flow cytometry platform that utilizes cartridge-based assays for sample preparation, significantly reducing handling time and increasing data reliability. The business model revolves around selling these automated systems and associated consumables, generating recurring revenue from the sale of cartridges and maintenance services. Accellix's technology is particularly beneficial for clients needing rapid and precise cell analysis, making it a valuable tool in the development and quality control of cell and gene therapies. The company is headquartered in San Jose, California, and Jerusalem, Israel, and is led by a diverse international team committed to innovation and customer satisfaction.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- San Jose, United States
- Employees
- 61
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2026 | $0 | — | BioMérieux | ↗ |
| LATE VC✓Equity / VC | Dec 2021 | $10M | $40M | BroadOak Capital Partners | ↗ |
Growth signals
Latest recorded traffic for Accellix is 2K monthly website visits, down 4.8% over the last three months. Accellix's team declined 15.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The Israel Innovation Authority
Series B and later2 investors entered at this stage
BioMérieux- BPBroadOak Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accellix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accellix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.